Literature DB >> 11555190

A possible role of hypervariable region 1 quasispecies in escape of hepatitis C virus particles from neutralization.

M Korenaga1, K Hino, Y Katoh, Y Yamaguchi, M Okuda, K Yoshioka, K Okita.   

Abstract

We examined serial changes in the hypervariable region 1(HVR1) quasispecies both in immune and nonimmune complexed hepatitis C virus (HCV) particles from 12 patients with chronic hepatitis C to elucidate the mechanism by which genetic diversification of HCV during the course of infection allows escape of virus from the humoural immune response. Immune and nonimmune complexes were separated by differential flotation centrifugation and immunoprecipitation, and their HVR1 quasispecies were determined by subcloning and sequencing. The presence of a specific antibody against a specific viral clone in serum was examined in two patients by Western blotting of the corresponding recombinant HVR1 protein. The distribution of HVR1 quasispecies in both immune and nonimmune complexes conspicuously changed over time in most of the patients studied. In seven patients, various HCV clones serially shifted from nonimmune complexes to immune complexes. In four of them, a group of clones with similar HVR1 sequences to each other remained predominant in nonimmune complexes, whereas minor clones with sequences considerably divergent from the predominant clones shifted from nonimmune complexes to immune complexes. These results suggest a mechanism for persistent infection of HCV, in which major HCV clones escape from neutralization by anti-HVR1 antibodies by generating considerably divergent minor 'decoy' clones which may be preferentially neutralized.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11555190     DOI: 10.1046/j.1365-2893.2001.00305.x

Source DB:  PubMed          Journal:  J Viral Hepat        ISSN: 1352-0504            Impact factor:   3.728


  8 in total

1.  Hepatitis C update.

Authors:  Shimian Zou; Leslie Forrester; Antonio Giulivi
Journal:  Can J Public Health       Date:  2003 Mar-Apr

2.  Dynamic coinfection with multiple viral subtypes in acute hepatitis C.

Authors:  Jennifer A Smith; Judith H Aberle; Vicki M Fleming; Peter Ferenci; Emma C Thomson; Peter Karayiannis; Angela R McLean; Heidemarie Holzmann; Paul Klenerman
Journal:  J Infect Dis       Date:  2010-11-10       Impact factor: 5.226

3.  Quasispecies of genotype 4 of hepatitis C virus genomes in Saudi patients managed with interferon alfa and ribavirin therapy.

Authors:  Ahmed A Al-Qahtani; George Kessie; Damian Dela Cruz; Faleh Z Al-Faleh; Mohammed N Al-Ahdal
Journal:  Ann Saudi Med       Date:  2010 Mar-Apr       Impact factor: 1.526

4.  The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus.

Authors:  Elisa Scarselli; Helenia Ansuini; Raffaele Cerino; Rosa Maria Roccasecca; Stefano Acali; Gessica Filocamo; Cinzia Traboni; Alfredo Nicosia; Riccardo Cortese; Alessandra Vitelli
Journal:  EMBO J       Date:  2002-10-01       Impact factor: 11.598

5.  Cross-reactivity of hypervariable region 1 chimera of hepatitis C virus.

Authors:  Bing-Shui Xiu; Shi-Gan Ling; Xiao-Guo Song; He-Qiu Zhang; Kun Chen; Cui-Xia Zhu
Journal:  World J Gastroenterol       Date:  2003-06       Impact factor: 5.742

Review 6.  Ribavirin contributes to eradicate hepatitis C virus through polarization of T helper 1/2 cell balance into T helper 1 dominance.

Authors:  Katsuhisa Nakatsuka; Masanori Atsukawa; Masumi Shimizu; Hidemi Takahashi; Chiaki Kawamoto
Journal:  World J Hepatol       Date:  2015-11-08

Review 7.  Hypervariable Region 1 in Envelope Protein 2 of Hepatitis C Virus: A Linchpin in Neutralizing Antibody Evasion and Viral Entry.

Authors:  Jannick Prentoe; Jens Bukh
Journal:  Front Immunol       Date:  2018-09-27       Impact factor: 7.561

8.  Enhancing the antigenicity and immunogenicity of monomeric forms of hepatitis C virus E2 for use as a preventive vaccine.

Authors:  Rob J Center; Irene Boo; Lilian Phu; Joey McGregor; Pantelis Poumbourios; Heidi E Drummer
Journal:  J Biol Chem       Date:  2020-04-16       Impact factor: 5.157

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.